Research programme: CD28 antagonists - TcLand/DebiopharmAlternative Names: Debio 0615; sc28AT - TcLand/Debiopharm
Latest Information Update: 16 Jul 2016
At a glance
- Originator TcLand
- Mechanism of Action CD28 antigen inhibitors; Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Transplant-rejection in France
- 29 May 2006 Preclinical trials in Autoimmune disorders in France (unspecified route)